Search

Your search keyword '"Ellert, Julia"' showing total 130 results

Search Constraints

Start Over You searched for: Author "Ellert, Julia" Remove constraint Author: "Ellert, Julia"
130 results on '"Ellert, Julia"'

Search Results

1. Comparison of Outcome After Percutaneous Coronary Intervention for De Novo and In-Stent Restenosis Indications.

2. Early vascular healing after implantation of the polymer-free biolimus-eluting stent or the ultrathin strut biodegradable polymer sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction

3. TCT-418 Impact of Diabetes on Clinical Outcomes After Percutaneous Coronary Intervention: 5-Year Results of the SORTOUT IX Trial Comparing the Polymer-Free Biolimus A9-Coated Stent to the Ultra-Thin Strut Biodegradable Polymer Sirolimus-Eluting Stent

4. TCT-708 5-Year Outcomes of Patients With Diabetes Mellitus Treated With a Sirolimus-Eluting or a Biolimus-Eluting Stent With Biodegradable Polymer: From the SORT OUT VII Trial

5. TCT-669 Impact of Acute Coronary Syndromes on Long-Term Clinical Outcomes After Percutaneous Coronary Intervention With the Biolimus-Coated BioFreedom Stent or Biodegradable Polymer Sirolimus-Eluting Orsiro Stent: From the SORT OUT IX Trial

7. Clinical outcomes three-year after revascularization with biodegradable polymer stents: ultrathin-strut sirolimus-eluting stent versus biolimus-eluting stent: from the Scandinavian organization for randomized trials with clinical outcome VII trial

8. Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention: The SORT OUT IX Trial

9. Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual‐therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent

10. Optical Coherence Tomography- Versus Angiography-Guided Magnesium Bioresorbable Scaffold Implantation in NSTEMI Patients

11. Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent

12. Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared With the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial

13. Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual‐therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent.

16. TCT-151 Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared With the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial

17. TCT-278 Five-Year Outcomes After Revascularization With the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Orsiro Stent or the Biodegradable Polymer Biolimus-Eluting Nobori Stent in Patients With and Without Acute Coronary Syndromes: From the SORT OUT VII Trial

18. Influence of Plaque Characteristics on Early Vascular Healing in Patients With ST-Elevation Myocardial Infarction

19. Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial

20. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study

24. Outcomes After Revascularization With a Polymer-Free Biolimus-Eluting BioFreedom Stent or a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Orsiro Stent in Patients With and Without Acute Coronary Syndromes: From the SORT OUT IX Trial

28. Clinical Outcomes Three Year After Revascularization With a Biodegradable Polymer Ultra-thin Strut Sirolimus-eluting Stent and a Biodegradable Polymer Biolimus-eluting Stent. From the SORT OUT VII trial

29. Early Changes in Malapposition Assessed with Optical Coherence Tomography after Biolimus-coated BioFreedom Stent or Sirolimus Eluting Orsiro Stent in Patients with ST-segment Elevation Myocardial Infarction

30. TCT-290 Outcomes After Revascularization With a Polymer-Free Biolimus-Eluting BioFreedom Stent or a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Orsiro Stent in Patients With and Without Acute Coronary Syndromes: From the SORT OUT IX Trial

31. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial

33. Impact of diabetes on clinical outcomes after revascularization with sirolimus‐eluting and biolimus‐eluting stents with biodegradable polymer from the SORT OUT VII trial

34. TCT-90 Clinical Outcomes Three Year After Revascularization With a Biodegradable Polymer Ultra-thin Strut Sirolimus-eluting Stent and a Biodegradable Polymer Biolimus-eluting Stent. From the SORT OUT VII trial.

36. TCT-737 Very Late Stent Thrombosis after Revascularization with Biodegradable Polymer Drug-Eluting Stents. From the SORT OUT VII Trial

42. Impact of diabetes on clinical outcomes after revascularization with sirolimus‐eluting and biolimus‐eluting stents with biodegradable polymer from the SORT OUT VII trial.

43. TCT-245 Association of intraoperative transit time flow after grafting and invasive coronary flow and pressure measurements before coronary artery bypass surgery.

44. TCT-348 Early Changes in Malapposition Assessed with Optical Coherence Tomography after Biolimus-coated BioFreedom Stent or Sirolimus Eluting Orsiro Stent in Patients with ST-segment Elevation Myocardial Infarction

46. Mutation des Chymase Gens im aktiven Zentrum und ihre Beziehung zu dermatologischen Erkrankungen

47. Mutation des Chymase Gens im aktiven Zentrum und ihre Beziehung zu dermatologischen Erkrankungen

48. Mutation des Chymase Gens im aktiven Zentrum und ihre Beziehung zu dermatologischen Erkrankungen

49. FIVE-YEAR PROGNOSTIC VALUE OF NO-REFLOW PHENOMENON AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

Catalog

Books, media, physical & digital resources